Research Article
The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI
Table 1
Baseline characteristics. Baseline characteristics of the population (
). Values are given as absolute numbers (%) or medians (25, 75 percentiles).
| Baseline characteristics | |
| Female gender | 3 (9%) | Age (yrs) | 58.0 (54.0, 68.0) | Current smokers | 16 (49%) | Previous smokers | 11 (33%) | BMI (kg/m2) | 27.7 (23.4, 28.6) | Hypertension | 11 (33%) | TDM2 | 4 (12%) | Previous coronary disease | 1 (3%) | Medication before index MI: | | ASA | 6 (18%) | Clopidogrel/prasugrel/tikagrelor | 2 (6%) | Warfarin | 1 (3%) | NOAC | 2 (6%) | Beta-blocker | 4 (12%) | ACE-I | 0 (0%) | AT-II-blocker | 5 (15%) | Statins | 6 (18%) | Diuretics | 4 (12%) | Aldosterone antagonists | 0 (0%) | Systolic BP (mmHg) | 126.0 (109.0, 144.0) | Diastolic BP (mmHg) | 80.0 (70.0, 99.5) | HR (beats/min) | 70.0 (65.0, 90) | Ischemic time (min) | 152 (122, 343) | CRP (mg/L) | 2.71 (1.00, 5.57) | Troponin T after PCI (μ/L) | 354 (123, 744) | Troponin T peak (μ/L) | 3434 (1250, 6967) | Culprit lesion: | | LAD | 16 (49%) | CX | 6 (18%) | RCA | 11 (33%) | Retrograde flow | 12 (36%) | Three-vessel disease | 6 (18%) | In-stent thrombus | 1 (3%) |
|
|
BMI: body mass index; T2DM: type II diabetes mellitus; ASA: acetysalicylic acid; NOAC: novel oral anticoagulant; ACE-I: angiotensin-converting enzyme inhibitor; AT-II-blocker: angiotensin receptor II-blocker; BP: blood pressure; HR: heart rate; CRP: C-reactive protein; PCI: percutan coronary intervention; LAD: left anterior descending artery; CX: circumflex artery; RCA: right coronary artery.
|